MedTrace Logo

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

NCT06531278 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-07-31

No results posted yet for this study

Summary

1. Evaluation of adebelimab in combination with irinotecan liposomes, oxaliplatin, fluorouracil, efficacy and safety of leucovorin in the first-line treatment of advanced metastatic pancreatic cancer
2. Construct the model of immunotherapy combined with chemotherapy for the treatment of pancreatic cancer liver metastasis

Conditions

  • Pancreatic Cancer Metastatic to Liver

Interventions

DRUG

Irinotecan liposome

* Patients are planned to receive irinotecan liposomal (60 mg/m2; d1) of every cycle. * 27 days a cycle

DRUG

Adebrelimab

* Patients are planned to receive Adebrelimab (20 mg/kg; d1) of every cycle. * 27 days a cycle

DRUG

Oxaliplatin

* Patients are planned to receive Oxaliplatin (85 mg/m2; d1) of every cycle. * 27 days a cycle

DRUG

Fluorouracil

* Patients are planned to receive fluorouracil (2400mg/m2; d1) of every cycle. * 27 days a cycle

DRUG

Calcium folinate

* Patients are planned to receive Calcium folinate (400mg/m2; d1) of every cycle. * 27 days a cycle

Sponsors & Collaborators

  • Jiang Long

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-16
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06531278 on ClinicalTrials.gov